Jefferies analyst Michael Yee downgraded Morphic (MORF) to Hold from Buy with a price target of $57, down from $60, after the company agreed to be acquired by Eli Lilly (LLY) for a purchase price of $57 per share in cash.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF: